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Pruritic papular eruption of HIV (PPE) represents
an intensely pruritic papular rash with greatest
severity on the extensor surfaces of extremities. It
is one of the most common cutaneous manifesta-
tions in HIV-infected individuals, in whom preva-
lence ranges between 11% and 46% depending on
geographic location.1-5 Persistent or recurrent PPE
despite effective antiretroviral therapy (ART) may
be associated with higher viral load at ART initia-
tion.6 Although pathogenesis is uncertain, an exag-
gerated immunologic reaction to arthropod bites
has been suggested because of geographical restric-
tion to the tropics, localization to the extremities,
similarity in histology, and increased peripheral
eosinophil counts.1 The optimum treatment path-
way is poorly defined because of lack of evidence
for different treatment modalities.
We report a case of recurrent PPE responding well
to oral thalidomide during a 3-month treatment
period.
CASE REPORT
A 44-year-old Zimbabwean woman living in the
United Kingdom since 1998 had HIV diagnosed in
2006. At the time of diagnosis, her CD4 count was
204 cells per cubic millimeter and viral load was
498,000 copies per milliliter. ART was started, which
resulted in a sustained suppression of HIV viremia
(viral load\40 copies/mL, CD4[600 cells per cubic
millimeter).
A year later a pruritic eruption developed starting
on the upper arms and spreading to the hands,
thighs, and back. Initial treatment with topical
betamethasone valerate 0.1% was effective, but a
relapse occurred 4 years later. On returning shethe Departments of Dermatologya and Histopathology,b
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rash affecting the trunk, arms, and legs. Examination
found numerous monomorphic hyperpigmented
papules on the extensor surface of the limbs and
on the trunk (Fig 1). The face, hands, feet, and
mucous membranes were spared.
Histologic analysis found a dermal perivascular
lymphocytic infiltrate with scattered eosinophils (Fig
2). The patient had PPE diagnosed based on the
clinical findings and histology.
Initial management with clobetasol propionate
0.05% ointment applied daily and high dose oral
antihistamineswasminimally effective. Thirty narrow-
band ultraviolet B phototherapy treatments led to
significant improvement, but a relapse occurred 2
weeks after termination of therapy.
Dapsone was considered but precluded because
of glucose-6-phosphate dehydrogenase deficiency.
Based on its efficacy in HIV-infected patients with
prurigo nodularis, the patient was prescribed a trial
of thalidomide at a dose of 100 mg daily.7 Before
commencement of treatment, the patient was coun-
selled regarding the risks of peripheral neuropathy
and teratogenicity. Two forms of contraception,
condoms and an intrauterine device, were used
throughout the treatment period.
We measured baseline severity and response to
treatment using the Dermatology Life Quality IndexJAAD Case Reports 2015;1:109-11.
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Fig 2. Pruritic papular eruption. Histologic confirmation
of the diagnosis shows a perivascular lymphocytic infil-
trate to the dermis with scattered eosinophils. (Hematox-
ylin-eosin stain.)
Fig 3. Graph shows the reduction in DLQI during the
treatment period from 26 down to 2.
Fig 4. Graph shows the reduction in VAS pruritus score
from 7 down to 1.
Fig 1. Pruritic papular eruption. Baseline appearance of
the upper limb shows a papular rash affecting the extensor
surface.
JAAD CASE REPORTS
MAY 2015
110 Wernham, Vydianath, and Chua(DLQI) and a 10-cm visual analogue score (VAS) for
pruritus. At the start of treatment, DLQI was 26/30
and VAS was 7/10. By 3 months of treatment, there
was almost complete resolution of symptoms with
a DLQI of 2/30 and VAS 1/10 (Figs 3 and 4).
Thalidomide was withheld at 3 months followed by
a 4-month remission. At the time of flare of the rash
and pruritus, thalidomide was recommenced at the
same daily dose, which led to similar improvement in
symptoms. Treatment was withheld by the patient at
5 months. She reported only few residual pruritic
papules, treated with topical betamethasone valerate
0.1% cream. PPE remains suppressed 5 months
after treatment discontinuation. There were no sig-
nificant adverse effects and no clinical evidence of
thalidomide-induced peripheral neuropathy during
either treatment period.
DISCUSSION
Differential diagnoses to consider in patients with
HIVand pruritus include PPE, prurigo nodularis, and
eosinophilic folliculitis. In our case, there was no
perifollicular inflammation on histology, which
would be expected with eosinophilic folliculitis. In
contrast to prurigo nodularis, the rash was papularrather than nodular, and the histology lacked typical
features of compact orthohyperkeratosis, acanthosis,
hypergranulosis, and papillary dermal fibrosis with
vertical alignment of collagen fibers.8
Few studies have identified beneficial therapeutic
approaches for PPE, and these are primarily obser-
vational studies, case series, or case reports.
Currently, there are no randomized controlled trials
undertaken to study interventions for PPE. For
diagnosis before ART commencement, dramatic re-
sponses have been documented in response to ART
initiation, with one study reporting complete reso-
lution without recurrence in 86% of their cohort.9
Initial skin treatment in these circumstances may
involve potent topical corticosteroids and high-dose
oral antihistamines.10,11 Narrowband ultraviolet B
and psoralen and ultraviolet A have been reported to
be effective, although the period of remissionmay be
brief.12 Other systemic treatments reported to be
effective in observational studies are dapsone and
pentoxyfylline.11,13
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for the development of peripheral neuropathy,
reported to occur in up to 55.6% of treated derma-
tologic patients.14 Compliance with pregnancy pre-
vention is important as exposure to the fetus can
lead to multiple birth defects, including phocomelia
and thumb absence/hypoplasia.15 The mechanism
for treating pruritic skin disease is not well charac-
terized but may involve a combination of actions.
Thalidomide acts as a central depressant with
sedative properties, which may be beneficial in
disrupting the itch-scratch cycle.16 In prurigo nod-
ularis, a local effect on proliferated neural tissue has
been suggested.17 Suppression of tumor necrosis
factor alfa and increased production of cytokines,
including interleukin-2 and interleukin-12 may also
play a role.18
Our decision to run a trial of thalidomide was
based on its efficacy and relative safety in a small
case series of patients with HIV and prurigo nod-
ularis and also its previously demonstrated efficacy
in other pruritic conditions. In the case series by
Maurer et al,7 all 8 subjects had a greater than 50%
reduction of pruritus over an average of 3.4 months,
and 7 of 8 patients had greater than 50% reduction in
clinical scoring. The treatment was generally well
tolerated without significant adverse effects,
although a reversible thalidomide-induced periph-
eral neuropathy developed in 3 of 8 patients. No
correlation was found between thalidomide and
reduction of CD4 count. Viral load was not
measured during thalidomide therapy.9 Our patient
had sustained virologic suppression throughout
both thalidomide treatment periods with viral load
less than 40 copies per milliliter and CD4 counts
between 600 and 800 cells per cubic millimeter.
We present a case of recurrent PPE responding to
oral thalidomide. Further studies are needed to
identify the optimum dosing regimen, efficacy, and
safety in this population.
REFERENCES
1. Resneck JS, Van Beek M, Furmanski L, et al. Etiology of pruritic
papular eruption with HIV infection in uganda. JAMA. 2004;
292:2614-2621.2. Colebunders R, Mann JM, Francis H, et al. Generalized papular
pruritic eruption in African patients with human immunode-
ficiency virus infection. AIDS. 1987;1:117-121.
3. Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin
disease in patients infected with human immunodeficiency virus
in Bangkok, Thailand. Ann Acad Med Singapore. 1995;24:528-533.
4. Rosatelli JB, Machado AA, Roselino AM. Dermatoses among
Brazilian HIV-positive patients: correlation with the evolu-
tionary phases of AIDS. Int J Dermatol. 1997;36:729-734.
5. Liautaud B, Pape J, DeHovitz JA, et al. Pruritic skin lesions. A
common initial presentation of acquired immunodeficiency
syndrome. Arch Dermatol. 1989;125:629-632.
6. Chua SL, Amerson EH, Leslie KS, et al. Factors associated with
pruritic papular eruption of human immunodeficiency virus
(HIV) infection in the antiretroviral therapy eta. Br J Dermatol.
2014;170:832-839.
7. Maurer T, Poncelet A, Berger T. Thalidomide treatment for
prurigo nodularis in human immunodeficiency virus-infected
subjects: efficacy and risk of neuropathy. Arch Dermatol. 2004;
140:845-849.
8. Weigelt N, Metze D, St€ander S. Prurigo nodularis: systematic
analysis of 58 histological criteria in 136 patients. J Cutan
Pathol. 2010;37:578-586.
9. Castelnuovo B, Byakwaga H, Menten J, Schaefer P, Kamya M,
Colebunders R. Can response of a pruritic papular eruption to
antiretroviral therapy be used as a clinical parameter to
monitor virological outcome? AIDS. 2008;22:269-273.
10. Navarini AA, Stoeckle M, Navarini S, et al. Antihistamines are
superior to topical steroids in managing human immunode-
ficiency virus (HIV)-associated papular pruritic eruption. Int J
Dermatol. 2010;49:83-86.
11. Lakshmi SJ, Rao GR, Ramalakshmi, Satyasree, Rao KA,
Prasad PG, Kumar YH. Pruritic papular eruptions of HIV: A
clinicopathologic and therapeutic study. Indian J Dermatol
Venereol Leprol. 2008;74:501-503.
12. Bellavista S, D’antuono A, Infusino SD, Trimarco R, Patrizi A.
Pruritic papular eruption in HIV: a case successfully treated
with NB-UVB. Dermatol Ther. 2013;26:173-175.
13. Berman B, Flores F, Burke G. Efficacy of pentoxifylline in the
treatment of papular pruritic eruption of HIV-infected persons.
J Am Acad Dermatol. 1998;38:955-959.
14. Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk
factors for thalidomide neuropathy: a prospective study of 135
dermatologic patients. J Invest Dermatol. 2002;119:1020-1026.
15. Martınez-Frıas ML. The thalidomide experience: review of its
effects 50 years later. Med Clin (Barc). 2012;139:25-32.
16. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta
Derm Venereol. 2000;80:24-25.
17. van den Broek H. Treatment of prurigo nodularis with
thalidomide. Arch Dermatol. 1980;116:571-572.
18. Corral L, Kaplan G. Immunomodulation by thalidomide and
thalidomide analogues. Ann Rheum Dis. 1999;58(Suppl 1):
I107-I113.
